Subscribe
Subscribe to IHE
Institute of Health Economics logo
My IHE Login
  • About IHE
    • About
    • History
    • Board of Directors
    • Corporate Reports
    • Partnerships & Affiliations
    • Staff Directory
    • Careers and Awards
    • Privacy Policy
  • Research & Programs
    • Health Technology Assessment
    • Health Economics
    • Industry Partnerships
    • Knowledge Transfer
    • Research Methodology Development
  • Publications
  • Events
    • Upcoming Events
    • Past Events
  • News
    • News
  • Contract Our Services
Home / Advanced Search

Advanced Search

Result Type

  • Publications
    • All Publications
    • Books
    • Consensus Statements
    • Economic Reports
    • Health Technology Assessments /
      Systematic Reviews
    • Health Topic Overviews / Scoping Reviews
    • HTA Policy
    • Journal Articles
    • Methodology Papers
    • Overview of Systematic Reviews
    • Rapid Reviews
    • Statistics Handbooks
    • Summary Reports
  • Other Resources
    • All Resources
    • Backgrounders
    • Clinical Practice Guidelines
    • Clinical Tools
    • Event Proceedings
    • Patient Resources
    • Presentations
    • Programs
  • News/Events
  • General Content

Years

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 1996-2013
    • 2013
    • 2012
    • 2011
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
    • 2005
    • 2004
    • 2003
    • 2002
    • 2001
    • 2000
    • 1999
    • 1998
    • 1997
    • 1996

Topics

  • Cancer
  • Chronic Diseases / Disorders
  • Community Health Centres
  • COVID-19
  • Diabetes
  • Diagnosis
  • Fetal Alcohol Spectrum Disorder (FASD)
  • Health Economics / Healthcare Costs
  • Health Measurement Tools
  • Health Policy
  • Health Technology Assessment
  • Health Topic Overviews
  • Healthcare Services
  • Infectious Diseases
  • Maternal and Child Health
  • Mental Health
  • Nurse Practitioners
  • Other
  • Pharmaceuticals
  • Prevention
  • Primary Care
  • Quality of Life
  • Scoping Reviews
  • Screening
  • Surveillance
  • Telehealth
  • Therapy

Authors

  • Akpinar, Ilke
  • Bond, Ken
  • Brown, Jasmine
  • Chojecki, Dagmara
  • Corabian, Paula
  • Guo, Bing
  • Institute of Health Economics, IHE
  • McCabe, Christopher
  • Moga, Carmen
  • Palfrey, Dan
  • Pollock, Michelle
  • Round, Jeff
  • Sproule, John
  • Sutton, Andrew J.
  • Tjosvold, Lisa
  • Tran, Dat
  • Warkentin, Lindsey
  • Wright, Erica
  • Yan, Charles

The outcome of IHE initiatives is providing better information for developing health policy and best medical practices. IHE disseminates information in many ways. In addition to publications in peer-reviewed journals, IHE produces books and a variety of reports synthesizing information in a particular field.

If you cannot find the publication or report you are seeking, please contact us at [email protected]. Thank you!

Refine your search by clicking filters to the left.

Results for: Dat Tran

Assessment of Costs of Avoidable Delays in Intensive Care Unit Discharge

August 19, 2020

| Sean M. Bagshaw, Dat Tran, Dawn Opgenorth, Xiaoming Wang, Danny Zuege, Armann Ingolfsson, Henry T. Stelfox, Thanh Nguyen

Delay in transfer from intensive care unit (ICU) may contribute to strained capacity. Using a population-based patient cohort in 17 ICUs in Alberta between 2012 and 2016, this paper describes the epidemiologic features and healthcare costs attributable to potentially avoidable delays in ICU discharge. Potentially avoidable discharge delay occurred in approximately 70% of ICU patients…

Outcome and Cost of Optimal Control of Dyslipidemia in Adults with High Risk for Cardiovascular Disease

March 23, 2020

| Dat Tran, Dan Palfrey, Thomas Lo, Robert Welsh

Summary: We examined the association between optimal control of dyslipidemia and mortality and healthcare costs in patients with high risk for cardiovascular disease (HRCVD) between 2012-2016 in Alberta, Canada. HRCVD patients who were optimally controlled had lower mortality and incurred modestly higher costs, compared to those who were not. Secondary prevention patients with…

Temporal Trends Of Pharmacologic Therapies For Patients With Chronic Obstructive Pulmonary Disease In Alberta, Canada

September 26, 2019

| Dat Tran, Ilke Akpinar, Irvin Mayers, Tatiana Makhinova, Philip Jacobs

The objective of this study, published in the International Journal of Chronic Obstructive Pulmonary Disease, was to describe the trends in pharmacologic treatment for patients newly diagnosed with chronic obstructive pulmonary disease (COPD) in Alberta, Canada.

The Costs of Industry-Sponsored Drug Trials in Canada

July 10, 2019

| Dat Tran, Ilke Akpinar, Philip Jacobs

This study, published in PharmacoEconomics – Open, reports exploratory analysis of the provincial and nationwide costs of industry-sponsored drug clinical trials (CTs) in Canada. The costs of industry-sponsored drug CTs completed in 2016 were Can$2.1 billion. In addition to the creation of knowledge, these trials play an important role in alleviating the healthcare cost burden…

Current and future direct healthcare cost burden of chronic obstructive pulmonary disease in Alberta, Canada

July 02, 2019

| Dat Tran, Thanh Nguyen, Arto Ohinmaa, Irvin Mayers, Philip Jacobs

OBJECTIVES: To examine the resource use and healthcare costs for chronic obstructive pulmonary disease (COPD) in Alberta, Canada between 2008 and 2016 and model the future costs to 2030.

Publicly funded clinical research in Canada

July 02, 2019

| Ilke Akpinar, Dat Tran, Philip Jacobs

Clinical research is funded by industry, governments, charities, and hospitals. It is important to know the economic commitment of the various funding bodies, but until now there has been no national source available which provides these data. We surveyed the major funders to provide such a measure. There is evidence that government and charity funding of medical research is a…

Association between strained ICU capacity and healthcare costs in Canada: A population-based cohort study

February 28, 2019

| Dat Tran, Thanh Nguyen, Dawn Opgenorth, Xiaoming Wang, Danny Zuege, David A. Zygun, Henry T. Stelfox, Sean M. Bagshaw

This study, published in the Journal of Critical Care, explores the association between strained ICU capacity and healthcare costs, and demonstrates the admissions to ICUs experiencing strain incur incremental costs, attributed to longer hospitalization and physician services.

Resource Use and Burden of Hospitalization, Outpatient, Physician, and Drug Costs in Short- and Long-term Care After Acute Myocardial Infarction

October 26, 2018

| Dat Tran, Robert Welsh, Arto Ohinmaa, Thanh Nguyen, Padma Kaul

Little is known about the resource use and cost burden of acute myocardial infarction (AMI) beyond the index event. We examined resource use and care costs during the first and each subsequent year, among patients with incident AMI.

Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: System-wide implementation and audit leads to improved value and patient outcomes

August 08, 2018

| S.P. Bisch, T. Wells, L. Gramlich, P. Faris, X. Wang, Dat Tran, Thanh Nguyen, S. Glaze, P. Chu, P. Ghatage, J. Nation, V. Capstick, H. Steed, J. Sabourin, G. Nelson

The Institute of Health Economics has contributed to a study published in the Journal Gynecologic Oncology. The study described the effects of Enhanced Recovery After Surgery (ERAS) guideline implementation in gynecologic oncology on length of stay, patient outcomes, and economic impact in Alberta. The study compared pre-and post-guideline implementation outcomes at two centers…

The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials

November 20, 2017

| Dat Tran, Ilke Akpinar, Richard Fedorak, Egon Jonsson, John Mackey, Lawrence Richer, Philip Jacobs

Purpose: In pharmaceutical clinical trials, industrial sponsors pay for study drugs and related healthcare services. We conducted a study to determine industry’s economic contribution of these trials to the Alberta healthcare system. Authors and Affiliations: Dat T. Tran1,2; Ilke Akpinar2 ; Richard N. Fedorak3 ; Egon Jonsson2 ; John R. Mackey4 ; Lawrence Richer5 ; Philip…

Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada

June 14, 2016

| Thanh Nguyen, Justin Ezekowitz, Dat Tran, Padma Kaul

  BACKGROUND: Eplerenone has been demonstrated as being cost effective for the treatment of patients with systolic heart failure (HF) and mild symptoms in several jurisdictions; however, its cost effectiveness is unknown in the context of Alberta, Canada.

  • Site Map
  • Privacy Policy
  • Contact Us & Subscribe
  • Home

Copyright © 2021 Institute of Health Economics

Institute of Health Economics 1200 10405 Jasper Avenue Edmonton, AB, Canada T5J 3N4

P: (1) 780.448.4881 F: (1) 780.448.0018
Email: [email protected]

Links

Canada

United States

United Kingdom

Other International

Journals

Health Economics Resources

Free Database Access

Never miss an update!

Subscribe to IHE